RTTNews BiotechCodex · 实盘不做把握 6/10不做原因:无增量信息
北京时间·🕒 发布 20:27:31·⟳ 抓取 20:30:16 +2m45s·⚡ 决策 09-08 21:49:56 +1h19m·48.8 天前
BioAge Labs启动BGE-102糖尿病黄斑水肿Phase 2给药，但暂无疗效读数
QUELL-DME首例给药本身确认研发进度，但该DME试验在8月5日公司更新中已披露计划于2026年中启动、数据预计2027年；本次没有新增疗效、监管突破、合作金额或近期收入现金流增量，短线正期望不足。
📄 原文RTTNews Biotech↗ 原文
BioAge Labs Initiates Phase 2 QUELL-DME Trial Of BGE-102 In Diabetic Macular Edema
BioAge Labs, Inc. (BIOA) announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Pha…
不做 BioAge Labs（BIOA.US）
不做BioAge Labs（BIOA.US）：首例给药是已预告临床日程兑现，暂无疗效/监管/商业化增量，盘中追多edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
BioAge Labs的官方稿确认BGE-102进入DME Phase 2给药阶段，方向偏正面；但这是临床开发进度节点，8月已预告启动，主要读数要到2027年下半年，且公司仍为临床阶段、当前收入主要非产品销售。因此事件对BIOA.US更像研发日程兑现，不足以支撑盘中追多。
消息传播链
- 公司一手宣布QUELL-DME首例受试者给药，确认从计划启动进入实际给药阶段。市场反应:RTTNews正文称盘前BIOA.US约9.75美元，较前收9.59美元上涨约1.63%。
- RTTNews转述公司公告，并补充前收和盘前报价。
- 公司此前已披露QUELL-DME计划于2026年中启动，数据预计2027年，削弱本次首例给药的预期差。
关键理由
- BGE-102若在DME验证口服NLRP3抑制，可扩展至其他炎症驱动视网膜疾病。
- 公司6月30日披露现金和可交易证券约3.813亿美元，按公司计划可支持运营至2029年，短期融资压力不构成本次主要矛盾。
主要风险
- 本次只启动给药，距离2027年下半年topline仍远，短线缺少可验证疗效催化。
- 8月5日公司已明确计划QUELL-DME于2026年中启动，当前公告的预期差有限。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-05 · 影响 weakens
8月公司已预告QUELL-DME中期启动和2027年读数，本次首例给药不是全新项目启动。
检索:BioAge Labs QUELL-DME planned initiate mid-2026 August 2026 business update 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-09-08 · 影响 weakens
本次公告没有DME疗效数据，主要读数预计2027年下半年，商业化和收入贡献仍无法量化。
检索:BioAge Labs BGE-102 QUELL-DME topline results 2027 no efficacy data first participant dosed 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例使本次BIOA.US从可关注降为不追多，等待QUELL-CV 2026年下半年读数或QUELL-DME疗效数据。
方向:同类研发进度节点方向偏正，但强度弱于疗效读数、监管批准或商业合作。
涨幅量级:缺少3条以上高相似且已量化的首例给药价格样本，不能据此设定可交易涨幅。
形态:当前可用样本更支持“研发日程兑现”而非强事件重估，且存在见光后缺少后续买盘的风险。
历史先例(按相似度)
- 相似度 7/10 BIOA 2026-06-16 BioAge宣布QUELL-CV Phase 2首例给药，topline预计2026年下半年。 原文 ↗
事件后 +1日 +3.3% · +2日 +0.8% · +3日 +4.7% · +4日 +8.2% · +5日 +12.5%
⚠锚前1-2日已异动20.6%>锚定日3.3% — 该行涨幅别用来定止盈止损
相似度依据:同公司、同BGE-102、同为Phase 2首例给药，但适应症为心血管风险而非DME。
经验:同类首例给药更偏研发进度确认，通常需要后续数据读数才能形成更强基本面催化。 - 相似度 6/10 BIOA 2026-08-05 BioAge二季度更新披露QUELL-DME计划2026年中启动、数据预计2027年。 原文 ↗
事件后 +1日 +2.6% · +2日 +6.7% · +3日 +4.3% · +4日 -2.8% · +5日 -4.5%
⚠相位不对齐(post!=target_pre) — 该行涨幅别用来定止盈止损
相似度依据:同公司同资产，8月公告已预告QUELL-DME启动计划和读数时间，是当前事件的前置披露。
经验:当后续公告只是兑现已披露研发日程，短线预期差要明显打折。
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 2,993 字
BioAge Labs, Inc. (BIOA) announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102 in adults with diabetic macular edema (DME).
The approximately 180-participant trial will evaluate BGE-102 both as a monotherapy and in combination with standard-of-care anti-VEGF therapy.
QUELL-DME is designed as a three-arm study, with participants randomized 1:1:1 to intravitreal anti-VEGF plus oral placebo, intravitreal anti-VEGF plus BGE-102 90 mg once daily, or sham intravitreal injection plus BGE-102 90 mg once daily.
The treatment period will run for 12 weeks, followed by a four-week follow-up period.
The primary endpoint is the change from baseline in best-corrected visual acuity (BCVA) at week 12.
Exploratory endpoints will assess retinal parameters as well as intraocular and plasma biomarkers.
Topline results from QUELL-DME are expected in the second half of 2027.
BGE-102 is a structurally novel, potent, orally available and brain-penetrant small-molecule inhibitor of NLRP3, an inflammatory pathway implicated in diabetic macular edema and other retinal diseases.
BioAge believes NLRP3 inhibition could address inflammatory mechanisms involved in DME, including IL-1ß and IL-18 release, pyroptosis, VEGF production and disruption of the blood-retinal barrier.
The company said the oral formulation of BGE-102 could potentially offer an alternative or complement to repeated intravitreal injections used in standard DME treatment.
The QUELL-DME results are also expected to help guide BioAge's development strategy for other NLRP3-driven retinal diseases, including geographic atrophy.
BioAge is simultaneously advancing BGE-102 in QUELL-CV, a Phase 2 dose-ranging trial in patients with obesity and elevated baseline inflammation.
QUELL-CV has completed enrollment, with topline data expected in the second half of 2026.
In a Phase 1 single- and multiple-ascending-dose trial involving healthy volunteers and participants with obesity and elevated systemic inflammation, BGE-102 demonstrated a well-tolerated profile and potential reductions in hsCRP and other inflammatory biomarkers.
BioAge is also developing long-acting injectable and oral small-molecule APJ agonists for obesity, while additional preclinical programs target pathways involved in metabolic aging based on insights from its human longevity-focused discovery platform.
BIOA closed Friday's trade at $9.59, up 0.95%. In the premarket trading, the stock is trading up 1.63% at $9.75.
For comments and feedback contact: editorial@rttnews.com
Business News
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.
The approximately 180-participant trial will evaluate BGE-102 both as a monotherapy and in combination with standard-of-care anti-VEGF therapy.
QUELL-DME is designed as a three-arm study, with participants randomized 1:1:1 to intravitreal anti-VEGF plus oral placebo, intravitreal anti-VEGF plus BGE-102 90 mg once daily, or sham intravitreal injection plus BGE-102 90 mg once daily.
The treatment period will run for 12 weeks, followed by a four-week follow-up period.
The primary endpoint is the change from baseline in best-corrected visual acuity (BCVA) at week 12.
Exploratory endpoints will assess retinal parameters as well as intraocular and plasma biomarkers.
Topline results from QUELL-DME are expected in the second half of 2027.
BGE-102 is a structurally novel, potent, orally available and brain-penetrant small-molecule inhibitor of NLRP3, an inflammatory pathway implicated in diabetic macular edema and other retinal diseases.
BioAge believes NLRP3 inhibition could address inflammatory mechanisms involved in DME, including IL-1ß and IL-18 release, pyroptosis, VEGF production and disruption of the blood-retinal barrier.
The company said the oral formulation of BGE-102 could potentially offer an alternative or complement to repeated intravitreal injections used in standard DME treatment.
The QUELL-DME results are also expected to help guide BioAge's development strategy for other NLRP3-driven retinal diseases, including geographic atrophy.
BioAge is simultaneously advancing BGE-102 in QUELL-CV, a Phase 2 dose-ranging trial in patients with obesity and elevated baseline inflammation.
QUELL-CV has completed enrollment, with topline data expected in the second half of 2026.
In a Phase 1 single- and multiple-ascending-dose trial involving healthy volunteers and participants with obesity and elevated systemic inflammation, BGE-102 demonstrated a well-tolerated profile and potential reductions in hsCRP and other inflammatory biomarkers.
BioAge is also developing long-acting injectable and oral small-molecule APJ agonists for obesity, while additional preclinical programs target pathways involved in metabolic aging based on insights from its human longevity-focused discovery platform.
BIOA closed Friday's trade at $9.59, up 0.95%. In the premarket trading, the stock is trading up 1.63% at $9.75.
For comments and feedback contact: editorial@rttnews.com
Business News
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。